PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.42 | 0.02 | -0.00 |
| FCF Yield | -120.48% | -333.15% | -116.57% | -34.89% |
| EV / EBITDA | -0.91 | 4.53 | -0.85 | -2.03 |
| Quality | ||||
| ROIC | -60.45% | 66.62% | -115.95% | -132.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.04 | 139.32 | 1.06 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 22.81% | 44.19% | -7.96% | 16.68% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | 7.29 | 0.17 | 0.26 |
| Interest Coverage | -129.68 | -23.52 | -26.43 | -13.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 2.29 | 0.00 | 0.00 |
| Cash Conversion Cycle | -835.10 | -36.90 | -168.69 | -344.16 |